NewTimeSpace News: BLUE MOON GROUP (06993.HK) announced on 15 July that based on preliminary review of unaudited consolidated management accounts, the Group expects consolidated loss attributable to owners of the Company for the six months ended 30 June 2026 to narrow by no less than 55% compared with the loss of approximately HK$435 million recorded in the same period last year. The loss reduction is mainly attributable to enhanced operational efficiency, implementation of knowledge-based marketing strategy and diversified channel expansion. The figures are preliminary and unaudited. Final results are expected to be published on or before 31 August 2026. Investors are advised to exercise caution.
NewTimeSpace News: LEPU BIO (02157.HK) announced on 15 July that Employee Representative Supervisor Ms. Zhao Lixuan has resigned for career development reasons, with effect from 15 July. Ms. Ren Fangyuan was elected to fill the vacancy effective the same date, serving until the expiry of the current Board of Supervisors term. Aged 25, Ms. Ren joined the Group in August 2025 and currently works as Specialist in Securities Department. She holds no shares in the Company and has no connections with the Company’s directors, supervisors, senior management or substantial shareholders.
NewTimeSpace News: LI NING (02331.HK) announced on 15 July its latest operating metrics for the second quarter of 2026. Group-wide retail waterfall of Li-Ning stores (excluding Li-Ning YOUNG) registered a low single-digit year-on-year decline in Q2, while the e-commerce virtual store business achieved mid single-digit growth. The total number of Li-Ning stores stood at 6,063 as at end-June, representing a net reduction of 12 stores quarter-on-quarter. Li-Ning YOUNG outlets totalled 1,516, with a net addition of 52 stores quarter-on-quarter. The data is prepared based on unaudited operating information and subject to revision. Investors are advised to exercise caution.
NewTimeSpace News: STANCHART (02888.HK) announced on 15 July that Manus Costello has been appointed Group Chief Financial Officer and Executive Director of the Board, subject to regulatory approval and effective immediately. The appointment was previously disclosed in an announcement dated 17 May 2026.
NewTimeSpace News: On 15 July 2026, RoboSense (02498.HK) edged higher in the afternoon. As of 15:30, the stock traded at HK$22.40, up 0.99%. Institutions maintain a bullish stance on the L4 RoboX theme for 2026.
NewTimeSpace (newtimespace.com) reported that Hong Kong semiconductor‑related themes experienced a volatile pullback, with HUA HONG GRACE (01347.HK) weakening. As of 13:27, the stock was quoted at HKD 168.100, down 1.98%.
NewTimeSpace News: SHOUCHENG(00697.HK) announced that a fund managed by an affiliate of Shoucheng Capital under the Group has invested in Shenzhen Shuoguang Precision Technology Co., Ltd. As a leader in laser precision manufacturing for high-end optical interconnect devices, Shuoguang Precision specialises in high value-added structured glass components for optical communication with self-developed ultra-precision optical manufacturing systems, boasting globally leading overall technological capabilities.
NewTimeSpace (newtimespace.com) reported that on July 15, 2026, the robotics theme in Hong Kong stocks fluctuated lower, while Midea Group (00300.HK) rose in volatile trading. As of 13:13, the stock was quoted at HKD 92.300, up 3.07%.
NewTimeSpace (newtimespace.com) News, On July 15, 2026, Hong Kong-listed AI agent concept stocks rallied collectively, with stocks such as MINIMAX-W (0100.HK), Zhipu (2513.HK), and Mininglamp Technology (2718.HK) delivering stellar performances. As of 10:20, MINIMAX-W (0100.HK) was quoted at HK$257.000, leading the gains among a crowd of large model concept stocks with an 11.74% surge.
NewTimeSpace News: CARRY WEALTH (00643.HK) plans to issue up to 179.97 million shares by placement, with estimated net proceeds of HKD 29 million.
NewTimeSpace News: GENFLEET-B (02595.HK) plans to issue in total 13.6 million shares by placement, with estimated net proceeds of HKD 466.9 million.
NewTimeSpace News: YANKUANG ENERGY (01171.HK) announced on 14 July 2026 that it expects net profit attributable to owners of the Company for the six months ended 30 June 2026 to reach approximately RMB7.2 billion, compared with RMB4.7 billion recorded in the same period last year. The expected non-recurring profit and loss-adjusted net profit attributable to shareholders stands at roughly RMB4.5 billion.
InSilico Medicine announced on July 15 that it has entered into a multi-faceted strategic alliance with Bora Pharmaceuticals to integrate InSilico Medicine's Pharma.AI platform with Bora's global drug development, manufacturing and commercialization capabilities. Specific cooperation details are subject to definitive agreements, and if fully implemented, the potential value of the proposed collaboration is expected to exceed US$2.5 billion.
CARsgen Therapeutics announced on July 15 that preliminary positive results of the CT041-CG4010 IIT trial for postoperative adjuvant consolidation therapy for G/GEJA have been accepted for poster presentation at the 2026 ESMO Congress, with the abstract to be published on October 19. Since enrollment began in May 2025, no participants have experienced postoperative recurrence or metastasis. Satri-cel was approved in June 2026 as the world's first solid tumor CAR-T cell therapy product.
361 Degrees voluntarily disclosed its Q2 2026 operating data on July 15, with both the main brand and kids wear brand offline channels recording mid-to-high single-digit positive growth in retail sales, and the e-commerce platform overall GMV recording high single-digit positive growth.
GenFleet Therapeutics entered into a placing agreement on July 14 with Morgan Stanley and CITIC CLSA to place 13.6 million new H-shares at HK$34.69 per share (approximately 9.71% discount to the closing price of HK$38.42), representing approximately 3.67% of the total issued shares, with estimated net proceeds of approximately HK$466.9 million. Approximately 75% of the net proceeds will be used for the core RAS pipeline (GFH276 40%, GFS202A 25%, preclinical IND applications 10%), 15% for R&D technology platform upgrades, and 10% for working capital. The Placing is not subject to shareholders' approval. The closing date is July 17, 2026, and the Company has committed to a 90-day lock-up period post-closing.
